Half-Year 2022 Financial and Clinical Trials Update slide image

Half-Year 2022 Financial and Clinical Trials Update

HY 2022: Highlights Roche Business Group sales growth of +5% driven by good performance of Pharmaceuticals and Diagnostics division ⚫ Pharma established products and new launches performing well; Diagnostics continuing with strong double-digit sales Core operating profit up +9% and Core EPS growth +11% (including +6.1%p net accretion Novartis share repurchase and 3.5%p from Ultomiris patent settlement) Cash flow • Operating Free Cash Flow of CHF 9.8bn, +21% growth driven by strong operating results and movements in net working capital . Net debt higher by CHF 2.7bn vs. Dec 31st 2021 Net financial result • Core net financial expense increased by CHF -370m driven by loss on equity securities IFRS • Net income +12% driven by the operating results and lower intangible assets amortization Growth rates at CER (Constant exchange Rates) 51
View entire presentation